Abstract
Antiepileptic drugs (AEDs) cover a broad spectrum of pathological conditions ranging from seizures following congenital or acquired brain disorders to behavioural and psychiatric disorders and recently neuropathic pain. The need for novel antiepileptics raises from the expanding field of indications as well as from the fact, that special seizure types are refractory to common AEDs. In addition, many of the conventional antiepileptic drugs exhibit an unfavourable side-effect profile. Since there is growing evidence, that NMDA receptor activation might play a crucial role in epilepsy, NMDA receptor antagonists have become compounds of interest in preventing and treating seizures. This review focuses on NMDA receptor antagonistic compounds, which are already in use for the treatment of epileptic seizures (i. e. MgSO4, felbamate) and compounds in clinical trials (i. e. remacemide, ADCI). Further interest is put on NMDA antagonists in preclinical and biological testing (memantine, dizocilpine, conantokins, Co101244 / PD174494, ifenprodil, arcaine, L-701,324, eliprodil, CGP40116, LY235959, LY233053, MRZ2 / 576, LU73068, 4-Cl-KYN). Some of the latter compounds are predominantely of academic interest (i. e. 4-Cl-KYN), others (i. e. dizocilpine, LY235959, LY233053) might be of therapeutical value when combined with conventional AEDs. In order to reduce adverse effects in antiepileptic medication using NMDA antagonists, special interest will be focused on subtype selective compounds. In this respect, Co 101244, a novel potent and selective NR1 / 2B NMDA receptor antagonist might be a lead for therapeutically promising compounds.
Keywords: antiepilptic drugs, nmda receptor, antiepileptic valproic acid vpa, magentic resonance imaging mri, adci, memantineconantokins, ifenprodil, eliprodil, glutamate site, cgp
Current Medicinal Chemistry
Title: The NMDA Receptor Complex: A Promising Target for Novel Antiepileptic Strategies
Volume: 8 Issue: 11
Author(s): B. K. Kohl and G. Dannhardt
Affiliation:
Keywords: antiepilptic drugs, nmda receptor, antiepileptic valproic acid vpa, magentic resonance imaging mri, adci, memantineconantokins, ifenprodil, eliprodil, glutamate site, cgp
Abstract: Antiepileptic drugs (AEDs) cover a broad spectrum of pathological conditions ranging from seizures following congenital or acquired brain disorders to behavioural and psychiatric disorders and recently neuropathic pain. The need for novel antiepileptics raises from the expanding field of indications as well as from the fact, that special seizure types are refractory to common AEDs. In addition, many of the conventional antiepileptic drugs exhibit an unfavourable side-effect profile. Since there is growing evidence, that NMDA receptor activation might play a crucial role in epilepsy, NMDA receptor antagonists have become compounds of interest in preventing and treating seizures. This review focuses on NMDA receptor antagonistic compounds, which are already in use for the treatment of epileptic seizures (i. e. MgSO4, felbamate) and compounds in clinical trials (i. e. remacemide, ADCI). Further interest is put on NMDA antagonists in preclinical and biological testing (memantine, dizocilpine, conantokins, Co101244 / PD174494, ifenprodil, arcaine, L-701,324, eliprodil, CGP40116, LY235959, LY233053, MRZ2 / 576, LU73068, 4-Cl-KYN). Some of the latter compounds are predominantely of academic interest (i. e. 4-Cl-KYN), others (i. e. dizocilpine, LY235959, LY233053) might be of therapeutical value when combined with conventional AEDs. In order to reduce adverse effects in antiepileptic medication using NMDA antagonists, special interest will be focused on subtype selective compounds. In this respect, Co 101244, a novel potent and selective NR1 / 2B NMDA receptor antagonist might be a lead for therapeutically promising compounds.
Export Options
About this article
Cite this article as:
Kohl K. B. and Dannhardt G., The NMDA Receptor Complex: A Promising Target for Novel Antiepileptic Strategies, Current Medicinal Chemistry 2001; 8 (11) . https://dx.doi.org/10.2174/0929867013372328
DOI https://dx.doi.org/10.2174/0929867013372328 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells
Current Topics in Medicinal Chemistry Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Mind-Body Practices and the Adolescent Brain: Clinical Neuroimaging Studies
Adolescent Psychiatry Transitional Polytherapy: Tricks of the Trade for Monotherapy to Monotherapy AED Conversions
Current Neuropharmacology Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Histamine H3 Receptor: A Potential Drug Target for the Treatment of Central Nervous System Disorders
Current Drug Targets - CNS & Neurological Disorders Integrated Application of Enhanced Replacement Method and Ensemble Learning for the Prediction of BCRP/ABCG2 Substrates
Current Bioinformatics Lessons Learned from Muscle Fatigue: Implications for Treatment of Patients with Hyperkalemic Periodic Paralysis
Recent Patents on Biotechnology Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Impact of Ancillary Subunits on Small-Molecule Interactions with Voltage-Gated Potassium Channels
Current Pharmaceutical Design Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies
Current Neuropharmacology Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry Antiepileptic Drugs for the Treatment of Impulsivity
Current Psychiatry Reviews Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging